Eli Lilly's Stock Drops Amidst Mixed Results and New Weight Loss Pill Developments
Eli Lilly's shares dropped over 14% after its obesity drug forglipron underperformed expectations in late-stage trials, marking its worst day in decades, while competitors like Novo Nordisk saw gains amid ongoing development of weight loss medications.